Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Antiviral resistance mutations limit the efficacy of therapy for chronic hepatitis B. At year
2, resistance to adefovir may occur as high as 25% in patients with history of lamivudine
resistance. Resistance to entecavir is reported to be 10% in lamivudine refractory patients
during the same period. However, combination of lamivudine and adefovir decreased the
adefovir resistance rate as low as 0% in the recent studies. By overcoming the antiviral
resistance, the efficacy of therapy will be maximized. This study is intended to compare the
efficacy of two strategies, combination of lamivudine and adefovir vs. entecavir monotherapy
in patients with lamivudine resistance.